OSE Immunotherapeutics Makes Strides with Tedopi®
OSE Immunotherapeutics, a biotech company dedicated to innovative solutions in immuno-oncology, has recently made significant clinical progress with their proprietary cancer vaccine, Tedopi® (OSE-2101). This 'off-the-shelf' neoepitope-based therapeutic cancer vaccine is being evaluated across various cancer indications with substantial unmet medical needs, marking a promising advancement in cancer treatment.
Overview of Clinical Trials
Several vital clinical trials are currently underway, showcasing the efficacy and potential of Tedopi® in treating different forms of cancer. Below are the highlights of the ongoing studies:
ARTEMIA: Phase 3 Registration Study
The ARTEMIA clinical trial protocol has gained global approval, and most countries involved have activated their sites. The full activation of the study is anticipated in the first half of the coming year. This international Phase 3 registration study focuses on exploring Tedopi® in a monotherapy setting for patients with second-line Non-Small Cell Lung Cancer (NSCLC). The enrollment of the first patients signifies a crucial step towards the product's eventual registration.
TEDOVA: Advancements in Ovarian Cancer Treatment
In the TEDOVA study, patient enrollment has been successfully completed. This Phase 2 clinical study evaluates the use of Tedopi® either solely or in combination with the well-known immunotherapy agent Keytruda® in treating ovarian cancer. Conducted by the French oncology cooperative group ARCAGY-GINECO, results from this important trial are expected by mid-2026, potentially paving the way for a groundbreaking treatment for multiple patients suffering from ovarian cancer.
CombiTED: Exploring Combination Therapies
The CombiTED study is also progressing well, with enrollment in this trial expected to be finalized soon. This three-arm Phase 2 study aims to assess the effectiveness of Tedopi® in combination with the anti-PD1 immune checkpoint inhibitor Opdivo® (nivolumab). The pivotal results of this study are anticipated in the latter half of 2026, with its main focus on second-line treatment in patients with metastatic NSCLC.
TEDOPaM: Investigating Pancreatic Cancer Treatment
In the TEDOPaM trial, the patient enrollment phase was completed last year. This non-comparative Phase 2 study aims to evaluate the potential of Tedopi® in combination with FOLFIRI chemotherapy for patients with advanced or metastatic pancreatic ductal adenocarcinoma. Results from this trial are anticipated in early 2025, providing further insights into the treatment options available for pancreatic cancer patients.
Expert Insights
Silvia Comis, MD, Head of Clinical Development and Regulatory Affairs at OSE Immunotherapeutics, emphasized the significance of their unwavering commitment to addressing diverse medical needs through innovative therapies. Highlighting the success of patient enrollment across multiple studies, she noted that the ongoing clinical program is fully on schedule, demonstrating a solid pipeline approach.
Dr. Alexandra Leary, the Chief Investigator of the TEDOVA study, expressed gratitude to all participants involved in the trial. She highlighted the unmet medical needs in patients with recurrent ovarian cancer and the importance of innovative maintenance strategies to extend periods free from chemotherapy.
About OSE Immunotherapeutics
OSE Immunotherapeutics is focused on developing first-in-class treatments in immuno-oncology and immuno-inflammation. With a strong commitment to collaboration with renowned academic institutions and biopharmaceutical firms, they are at the forefront of developing transformative medicines aimed at significantly improving patient outcomes. The company operates primarily from Nantes and Paris and is listed on Euronext.
Frequently Asked Questions
What is Tedopi®?
Tedopi® (OSE-2101) is an innovative 'off-the-shelf' neoepitope-based therapeutic cancer vaccine currently undergoing evaluation for various cancers with unmet needs.
What are the main clinical trials for Tedopi®?
The main trials include ARTEMIA for NSCLC, TEDOVA for ovarian cancer, CombiTED for NSCLC with immunotherapy combinations, and TEDOPaM for pancreatic cancer.
When can we expect results from these trials?
Results from the TEDOVA trial are expected in mid-2026, while the CombiTED trial results will likely be available in the latter half of 2026, with TEDOPaM outcomes anticipated in early 2025.
How does OSE Immunotherapeutics work with partners?
OSE Immunotherapeutics collaborates with leading academic institutions and biopharmaceutical companies to develop and market transformative therapies for serious diseases.
Where is OSE Immunotherapeutics based?
The company operates between Nantes and Paris and is publicly traded on Euronext.
